Pharvaris NV
PHVSHealthcare|Biotechnology|Netherlands
$35.02
-0.86 (-2.39%)
Tangible Book
$4.18
Earnings Power
$4.31
About
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
Stock Price
+76.6%(1Y)
Pipeline Summary
8 total trials0
Phase 1
3
Phase 2
6
Phase 3
0
Phase 4
ENROLLING_BY_INVITATION: 1Recruiting: 3Active: 1Completed: 3
Active Trials (4)
Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 Receptor
NCT05834777Intradialytic Hypotension
Phase 3Recruiting
Enrollment: 26 participants
Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
NCT06669754Hereditary Angioedema (HAE)
Phase 3Active
Enrollment: 81 participants
Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant IR Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency
NCT07266805Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)
Phase 3Recruiting
Enrollment: 32 participants
Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
NCT06679881Hereditary Angioedema (HAE)
Phase 3Recruiting
Enrollment: 170 participants
BioScore
5.9/10
Watchlist
Ownership
Recent Insider Trades
Lesage AnneSELL
2026-06-3076,172 shares @ $35.39
Schikan Johannes Gerardus Christiaan PetrusSELL
2026-06-3037,600 shares @ $35.41
Schikan Johannes Gerardus Christiaan PetrusSELL
2026-06-292,400 shares @ $35.1
Lu PengSELL
2026-06-2629,700 shares @ $34.3
Lesage AnneSELL
2026-06-254,600 shares @ $35.12
Recent News
2026-07-02 02:02:26
2026-06-30 00:03:08
2026-06-25 18:01:27
Data last updated: Jul 13, 2026, 12:42 PM